Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults

E. Anders Kolb, Brian H. Kushner, Richard Gorlick, Caroline Laverdiere, John H. Healey, Michael P. LaQuaglia, Andrew G. Huvos, Jing Qin, Ha Thanh Vu, Leonard Wexler, Suzanne Wolden, Paul A. Meyers

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs.

Original languageEnglish (US)
Pages (from-to)3423-3430
Number of pages8
JournalJournal of Clinical Oncology
Volume21
Issue number18
DOIs
StatePublished - Sep 15 2003
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Disease-Free Survival
Young Adult
Drug Therapy
Survival Rate
Neoplasm Metastasis
Ifosfamide
Survival
Vincristine
Etoposide
Therapeutics
Doxorubicin
Cyclophosphamide
Disease Progression
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kolb, E. A., Kushner, B. H., Gorlick, R., Laverdiere, C., Healey, J. H., LaQuaglia, M. P., ... Meyers, P. A. (2003). Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. Journal of Clinical Oncology, 21(18), 3423-3430. https://doi.org/10.1200/JCO.2003.10.033

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. / Kolb, E. Anders; Kushner, Brian H.; Gorlick, Richard; Laverdiere, Caroline; Healey, John H.; LaQuaglia, Michael P.; Huvos, Andrew G.; Qin, Jing; Vu, Ha Thanh; Wexler, Leonard; Wolden, Suzanne; Meyers, Paul A.

In: Journal of Clinical Oncology, Vol. 21, No. 18, 15.09.2003, p. 3423-3430.

Research output: Contribution to journalArticle

Kolb, EA, Kushner, BH, Gorlick, R, Laverdiere, C, Healey, JH, LaQuaglia, MP, Huvos, AG, Qin, J, Vu, HT, Wexler, L, Wolden, S & Meyers, PA 2003, 'Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults', Journal of Clinical Oncology, vol. 21, no. 18, pp. 3423-3430. https://doi.org/10.1200/JCO.2003.10.033
Kolb, E. Anders ; Kushner, Brian H. ; Gorlick, Richard ; Laverdiere, Caroline ; Healey, John H. ; LaQuaglia, Michael P. ; Huvos, Andrew G. ; Qin, Jing ; Vu, Ha Thanh ; Wexler, Leonard ; Wolden, Suzanne ; Meyers, Paul A. / Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 18. pp. 3423-3430.
@article{98085bd475e84761b48c72e4784a27b0,
title = "Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults",
abstract = "Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82{\%}; overall survival (OS) is 89{\%}. The 4-year EFS rate for patients with distant metastases is 12{\%}; the OS rate is 17.8{\%}. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs.",
author = "Kolb, {E. Anders} and Kushner, {Brian H.} and Richard Gorlick and Caroline Laverdiere and Healey, {John H.} and LaQuaglia, {Michael P.} and Huvos, {Andrew G.} and Jing Qin and Vu, {Ha Thanh} and Leonard Wexler and Suzanne Wolden and Meyers, {Paul A.}",
year = "2003",
month = "9",
day = "15",
doi = "10.1200/JCO.2003.10.033",
language = "English (US)",
volume = "21",
pages = "3423--3430",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults

AU - Kolb, E. Anders

AU - Kushner, Brian H.

AU - Gorlick, Richard

AU - Laverdiere, Caroline

AU - Healey, John H.

AU - LaQuaglia, Michael P.

AU - Huvos, Andrew G.

AU - Qin, Jing

AU - Vu, Ha Thanh

AU - Wexler, Leonard

AU - Wolden, Suzanne

AU - Meyers, Paul A.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs.

AB - Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs.

UR - http://www.scopus.com/inward/record.url?scp=0142058029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142058029&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.10.033

DO - 10.1200/JCO.2003.10.033

M3 - Article

C2 - 12972518

AN - SCOPUS:0142058029

VL - 21

SP - 3423

EP - 3430

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -